Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CD64-28z CAR-T
- Development stage
- Preclinical
- Lead developer
- University of Colorado Anschutz Medical Campus
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Administration
- Intravenous
01
Overview
CD64-28z CAR-T is an experimental second-generation chimeric antigen receptor (CAR) T-cell therapy designed to target CD64 (also known as FcγRI), a high-affinity Fc receptor for IgG. CD64 is highly expressed on monocytic acute myeloid leukemia (AML) cells and monocytic leukemia stem cells (m-LSCs), which are often resistant to standard-of-care treatments like venetoclax and azacitidine. The CAR construct incorporates a CD28 costimulatory domain and a CD3ζ signaling domain. Developed by researchers at the University of Colorado, CD64-28z CAR-T has shown potent anti-leukemic activity in preclinical models, including the elimination of CD64+ leukemia cell lines and primary patient-derived AML cells in vivo and ex vivo. It is being developed as a potential treatment for relapsed or refractory monocytic AML (FAB M5 subtype).
- Other names
- CD64-directed CAR-T cellsCD-64-directed CAR-T cellsCD 64-directed CAR-T cellsCD64-28zCD-64-28zCD 64-28z
02
Targets
FCGR1A (High affinity immunoglobulin gamma fc receptor I)
Beyond the preview
Go deeper on CD64-28z CAR-T.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CD64-28z CAR-T.